Your browser doesn't support javascript.
loading
Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan.
Guijarro, Francesca; Bataller, Alex; Diaz-Beyá, Marina; Garrido, Ana; Coll-Ferrà, Christelle; Vives, Susana; Salamero, Olga; Valcárcel, David; Tormo, Mar; Arnan, Montserrat; Sampol, Antònia; Castaño-Díez, Sandra; Martínez, Carmen; Suárez-Lledó, María; Fernández-Avilés, Francesc; Hernández-Boluda, Juan Carlos; Ribera, Josep Maria; Rovira, Montserrat; Brunet, Salut; Sierra, Jorge; Esteve, Jordi.
Affiliation
  • Guijarro F; Hospital Clinic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Bataller A; Hospital Clinic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Diaz-Beyá M; Josep Carreras Leukemia Research Institute, Badalona, Spain.
  • Garrido A; Hospital Clinic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Coll-Ferrà C; Josep Carreras Leukemia Research Institute, Badalona, Spain.
  • Vives S; Josep Carreras Leukemia Research Institute, Badalona, Spain.
  • Salamero O; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Valcárcel D; Josep Carreras Leukemia Research Institute, Badalona, Spain.
  • Tormo M; ICO-Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Badalona, Spain.
  • Arnan M; Universitat de Vic-Universitat Central de Catalunya, Vic, Spain.
  • Sampol A; Josep Carreras Leukemia Research Institute, Badalona, Spain.
  • Castaño-Díez S; ICO-Hospital Germans Trias i Pujol, Institut Català d'Oncologia, Badalona, Spain.
  • Martínez C; Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Suárez-Lledó M; Hospital Vall d'Hebron, VHIO, Barcelona, Spain.
  • Fernández-Avilés F; Hospital Vall d'Hebron, VHIO, Barcelona, Spain.
  • Hernández-Boluda JC; Hospital Clínico de Valencia, INCLIVA Research Institute, Valencia, Spain.
  • Ribera JM; Institut Català d'Oncologia, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
  • Rovira M; Hospital Son Espases, Institut d'Investigació Sanitària Illes Balears (IdISABa), Palma, Spain.
  • Brunet S; Hospital Clinic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Sierra J; Hospital Clinic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Esteve J; Josep Carreras Leukemia Research Institute, Badalona, Spain.
Bone Marrow Transplant ; 57(8): 1304-1312, 2022 08.
Article in En | MEDLINE | ID: mdl-35643942
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Hematopoietic Stem Cell Transplantation / Graft vs Host Disease / Myeloproliferative Disorders Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Hematopoietic Stem Cell Transplantation / Graft vs Host Disease / Myeloproliferative Disorders Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2022 Document type: Article Affiliation country: Country of publication: